

Mario Domenico Rizzato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6377960/publications.pdf>

Version: 2024-02-01

31
papers

273
citations

1051969

10
h-index

1051228

16
g-index

33
all docs

33
docs citations

33
times ranked

457
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study. <i>European Journal of Cancer</i> , 2022, 166, 165-175.	1.3	17
2	Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 370-379.	4.2	31
3	Sequential Treatment of Sorafenibâ€“Regorafenib Versus Sorafenibâ€“Physicianâ€™s Choice: A Propensity Score-Matched Analysis. <i>Targeted Oncology</i> , 2021, 16, 401-410.	1.7	5
4	Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma: efficacy, safety and prognostic factors. <i>Digestive and Liver Disease</i> , 2021, 53, S10.	0.4	0
5	Regorafenib versus cabozantinib as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3665-3671.	1.2	12
6	Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib. <i>Hepatology Research</i> , 2021, 51, 796-802.	1.8	4
7	Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases. <i>JCO Precision Oncology</i> , 2021, 5, 1166-1177.	1.5	55
8	Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma. <i>ESMO Open</i> , 2021, 6, 100190.	2.0	12
9	Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience. <i>Targeted Oncology</i> , 2021, 16, 653-661.	1.7	0
10	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2020, 15, 773-785.	1.7	12
11	Validation and refinement of PROSASH model using the neutrophilâ€“lymphocyte ratio in patients with HCC receiving sorafenib. <i>Liver Cancer International</i> , 2020, 1, 6-11.	0.2	0
12	405MO Personalized circulating tumour DNA assay for the detection of minimal residual disease in CRC patients after resection of metastases. <i>Annals of Oncology</i> , 2020, 31, S413.	0.6	3
13	Association of <i>NOS3</i> and <i>ANGPT2</i> Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. <i>Clinical Cancer Research</i> , 2020, 26, 4485-4493.	3.2	13
14	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. <i>PLoS ONE</i> , 2020, 15, e0232449.	1.1	29
15	Fluoropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. <i>International Journal of Cancer</i> , 2020, 147, 3177-3188.	2.3	17
16	Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib. <i>Medicine (United States)</i> , 2020, 99, e19958.	0.4	13
17	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
18	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0

#	ARTICLE	IF	CITATIONS
19	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
20	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
21	Capecitabine in advanced hepatocellular carcinoma: A multicenter experience. Digestive and Liver Disease, 2019, 51, 1713-1719.	0.4	18
22	Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: results of INNOVATE study. Annals of Oncology, 2019, 30, iv113.	0.6	0
23	OC.07.6 CAPECITABINE IN ADVANCED HEPATOCELLULAR CARCINOMA: A MULTICENTER EXPERIENCE. Digestive and Liver Disease, 2019, 51, e96.	0.4	0
24	Capecitabine in advanced hepatocellular carcinoma: a multicenter experience. Digestive and Liver Disease, 2019, 51, e40.	0.4	0
25	THU-448-Multicentric prospettive study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: Interim analysis of INNOVATE study. Journal of Hepatology, 2019, 70, e356.	1.8	0
26	Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort. Gastrointestinal Tumors, 2019, 6, 71-80.	0.3	4
27	Advanced intrahepatic cholangiocarcinoma (iCCA) treated with arterial-directed therapies (ADT): Outcomes and safety from a multicenter Italian experience. Annals of Oncology, 2018, 29, viii261.	0.6	1
28	Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: TheÂTOREADOR Study. Clinical Colorectal Cancer, 2018, 17, e601-e615.	1.0	18
29	TRUST: phase II trial of induction chemotherapy (CT) with FOLFOXIRI plus bevacizumab (BV) followed by chemo-radiotherapy (CRT) plus BV and surgery in locally advanced rectal carcinoma (LARC). Annals of Oncology, 2016, 27, iv43.	0.6	0
30	TRUST: Phase II trial of induction chemotherapy (CT) with FOLFOXIRI + bevacizumab (BV) followed by chemo-radiotherapy (CRT) + BV and surgery in locally advanced rectal carcinoma (LARC). Annals of Oncology, 2016, 27, vi170.	0.6	1
31	Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience. Journal of Cancer Research and Clinical Oncology, 2016, 142, 679-685.	1.2	7